EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Differential effects of translation inhibitors on Plasmodium berghei liver stage parasites

James L McLellan iD, Kirsten K Hanson iD

Life Science Alliance · 2024

DOI: 10.26508/lsa.202302540 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Life Science Alliance, 2024. Verfasst von James L McLellan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology and STCEID, University of Texas at San Antonio, San Antonio, TX, USA. Hauptthemen laut MEDLINE: Parasites, Antimalarials. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Increasing numbers of antimalarial compounds are being identified that converge mechanistically at inhibition of cytoplasmic translation, regardless of the molecular target or mechanism. A deeper understanding of how their effectiveness as liver stage translation inhibitors relates to their chemoprotective potential could prove useful. Here, we probed that relationship using the Plasmodium berghei –HepG2 liver stage infection model. After determining translation inhibition EC 50 s for five compounds, we tested them at equivalent effective concentrations to compare the parasite response to, and recovery from, a brief period of translation inhibition in early schizogony, followed by parasites to 120 h post-infection to assess antiplasmodial effects of the treatment. We show compound-specific heterogeneity in single parasite and population responses to translation inhibitor treatment, with no single metric strongly correlated to the release of hepatic merozoites for all compounds. We also demonstrate that DDD107498 is capable of exerting antiplasmodial effects on translationally arrested liver stage parasites and uncover unexpected growth dynamics during the liver stage. Our results demonstrate that translation inhibition efficacy does not determine antiplasmodial efficacy for these compounds.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ParasitesAntimalarialsAnimalsPlasmodium bergheiLiverMerozoites

Substanzen

Antimalarials

Autor:innen und Institutionen

  • Department of Molecular Microbiology and Immunology and STCEID, University of Texas at San Antonio, San Antonio, TX, USA.
  • Department of Molecular Microbiology and Immunology and STCEID, University of Texas at San Antonio, San Antonio, TX, USA kirsten.hanson@utsa.edu.

ORCID-Profile: James L McLellan, Kirsten K Hanson

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases

Zitieren

APA

McLellan, J. L., & Hanson, K. K. (2024). Differential effects of translation inhibitors on Plasmodium berghei liver stage parasites. Life Science Alliance. https://doi.org/10.26508/lsa.202302540

Vancouver

McLellan JL, Hanson KK. Differential effects of translation inhibitors on Plasmodium berghei liver stage parasites. Life Science Alliance. 2024. doi:10.26508/lsa.202302540

BibTeX
@article{McLellan2024,
  author = {McLellan, James L and Hanson, Kirsten K},
  title = {Differential effects of translation inhibitors on Plasmodium berghei liver stage parasites},
  journal = {Life Science Alliance},
  year = {2024},
  doi = {10.26508/lsa.202302540}
}
Kostenlos starten →